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and recovery of persons with schizophrenia (Buckley et al., 2009; Green
et al., 2004a). Studies show that cognitive performance is one to two stan-
dard deviations below average in schizophrenia (Dickinson et al., 2003;
Gold, 2004) and that such deﬁcits span neurocognitive and social–cogni-
tive domains (Nuechterlein et al., 2004), lead to poor long-termoutcomes
(Green et al., 2004a), and may become worsened when those with the
disorder misuse substances (Potvin et al., 2012). However, while alcohol
and cannabismisuse has been associatedwith poorer cognitive outcomes
among healthy adults (Courtney & Polich, 2009; D’Souza et al., 2004),
these relations are much more complex in schizophrenia.
Studies of the cognitive impact of alcohol or cannabis misuse in
schizophrenia have yielded mixed results (Potvin et al., 2012).
Cannabis-misusing schizophrenia patients tend to demonstrate better
cognitive performance than their non-cannabis-misusing counterparts
(Coulston et al., 2007; DeRosse et al., 2010; Jockers-Scherübl et al.,
2007; Løberg & Hughdahl, 2009; Rabin et al., 2011; Rodriguez-Sanchez
et al., 2010; Sevy et al., 2001; Yücel et al., 2012), yet a few studies have
reported no between-group differences (Bahorik et al., 2014; Mata
et al., 2008; Scholes & Martin-Iverson, 2010). In contrast, alcohol-
misusing schizophrenia patients exhibit worse cognitive performance
than their non-alcohol-misusing counterparts (Allen & Remy, 2001;
Bowie et al., 2005; Manning et al., 2009; Mohamed et al., 2006; Thoma
et al., 2006), with a few studies reporting no between-group differences
(Addington & Addington, 1997; Allen et al., 2000; Nixon et al., 1996).
Regarding themixed ﬁndings reported between substancemisusing
and non-misusing schizophrenia patients on cognitive outcomes, sever-
al questions about the way in which the severity associated with
alcohol, cannabis, or the concurrent use of these substances impacts
cognition among those seeking treatment to improve these deﬁcits re-
main. Variability in the degree of severity, which has been deﬁnedwith-
in the context of the problems that necessitate substance use treatment
(McLellan et al., 1980), may reveal important cognitive differences
within this subgroup. To date, however, the way in which such misuse⁎ Corresponding author at: University of Pittsburgh School of Social Work, 2117
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remained largely unexamined. The objectives of this study were to in-
vestigate cognitive performance differences between SMS, schizophre-
nia, and control participants, and examine whether alcohol or
cannabis severity impacts cognition within the SMS sample.
Participants included 32 SMS, 28 schizophrenia, and 37 control partic-
ipants partaking in studies of Cognitive Enhancement Therapy (CET
[Hogarty andGreenwald, 2006]) at the University of Pittsburgh. Inclusion
criteria for schizophrenia outpatients consisted of an IQ ≥ 80; age
18 to 60; antipsychotic medication adherent; and schizophrenia/
schizoaffective disorder conﬁrmed by the Structured Clinical Interview
forDSM-IV (SCID [First et al., 2000]). Inclusion criteria for SMSoutpatients
consisted of these criteria, as well as Addiction Severity Index (ASI
[McLellan et al., 1980]) severity ratings ≥ 4 for alcohol or cannabis,
and signiﬁcant cognitive and social disability conﬁrmed by the Cognitive
Styles and Social Cognition Eligibility Interview (Hogarty and Greenwald,
2006). Cognitive and social disability criteria were part of the inclusion
criteria for SMS patients to ensure that such participants had sufﬁcient
disability to need treatment. Inclusion criteria for controls consisted of
an age 18 to 50; free from psychiatric diagnosis per the SCID; no sub-
stance abuse within 3 months. Participants’ characteristics are presented
in Table 1.
The Measurement and Treatment Research to Improve Cognition in
Schizophrenia (MATRICS [Green et al., 2004b]) Consensus Cognitive
Battery assessed neurocognition. This battery assesses processing
speed, verbal/non-verbal working memory, attention/vigilance, ver-
bal/visual learning, and problem solving.
The Mayer–Salovey–Caruso Emotional Intelligence Test (MSCEIT
[Mayer et al., 2003]) and the Penn Emotion Recognition Test (Kohler
et al., 2000) assessed social cognition. The MSCEIT consists of 141-
items, is scored using consensus norms with a mean (SD) of 100 (15),
and has been validated in normative (Mayer et al., 2003) and psychiatric
samples (Eack et al., 2010). The Penn Emotion Recognition Test (Kohler
et al., 2000) assessed facial emotion perception.
The 35-item substance use scale of the ASI (McLellan et al., 1980)
assessed substance misuse and severity. SMS patients were asked
about current (total dayswithin 30 days) and lifetime (total years) alco-
hol and cannabis use. Severity was rated on a 0 to 10 point scale andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Demographic and clinical characteristics of healthy individuals, and participants with schizophrenia-spectrum disorders with and without substance misuse problems (N = 97).
Variable HC (n = 37) SMS (n = 32) SZ (n = 28) Analysisa
M SD M SD M SD p Direction
Age 25.81 5.66 39.25 12.91 27.39 6.67 b .001 HC b SZ b SMS
IQ 104.19 9.27 99.72 11.13 104.25 14.24 .199
N % N % N % p Direction
Male 27 73.0% 22 68.8% 21 75.0% .856
White 31 83.8% 15 46.9% 12 42.9% b .001 HC b SMS, SZ
Diagnosisb
Schizoaffective disorder – – 16 50.0% 12 42.9%
Schizophrenia – – 15 46.9% 16 57.1%
Addiction Severityc
High Alcohol – – 8 8.2% – –
Moderate Alcohol – – 24 24.7% – –
High Cannabis – – 10 10.3% – –
Moderate Cannabis – – 22 68.7% – –
Current Used
Alcohol – – 15 46.9% – –
Cannabis – – 17 53.1% – –
Note. HC = Healthy controls; SMS = substance misusing schizophrenia patients; SZ = patients with schizophrenia.
a χ2 test or analysis of variance test, two tailed, for signiﬁcant differences between healthy control, schizophrenia, and SMS participants.
b Diagnosis = schizophrenia or schizoaffective disorder as conﬁrmed by the SCID.
c Addiction Severity = ASI addiction severity ratings were used to assess the degree of severity associated with SMS patients current use of alcohol or cannabis, their lifetime use of
these substances, and treatment history. Severity was rated on a 0 to 10 point scale with regard to these criteria, and patients with severity ≥ 4 were enrolled in this study. ASI severity
score cut-points were used to distinguish clinically meaningful subgroups of SMS patients with moderate (severity 4–5) and high (severity 6–9) severity.
d Current Use = Number of days in the past 30 days SMS patients used alcohol or cannabis as identiﬁed by the ASI. Patients who disclosed usewere coded “yes = 1”; patients who did
not disclose use were coded “no = 0”.
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patient’s impression of their treatment need; higher scores signaled
both greater severity and treatment need. ASI cut-points (McLellan
et al., 1980) were used to distinguish clinically meaningful subgroups
of SMSpatientswithmoderate (scores, 4–5) or high (scores, 6–9) sever-
ity for post-hoc analyses.
Participants were recruited from the Pittsburgh area. Diagnostic in-
terviewswere carried out by staff using the SCID supervised by diagnos-
ticians. Staff using the ASI carried out severity assessments; SMS
patients with ratings ≥ 4 were enrolled. After determining eligibility,
testers administered cognitive measures to participants. Pre-
treatment data were analyzed for patients partaking in CET studies.
This research was approved and reviewed annually by the University
of Pittsburgh Institutional Review Board. Participants provided written
informed consent.
Comparisons of overall performance differences on domain mea-
sures of neurocognition and social cognition between control, SMS,
and schizophrenia participants adjusting for sex, age, race, and IQ re-
vealed signiﬁcant differences in neurocognitive function across the do-
mains measured (all p b .027), and in emotion accuracy, emotion
understanding, and total emotional intelligence social–cognitive func-
tion (all p b .013). Planned follow-up pairwise comparisons showed
that schizophrenia and SMS participants had marked impairment in
these domains of cognitive function compared to controls. Few differ-
ences in neurocognitive performance were observed between schizo-
phrenia and SMS participants, and no differences in social–cognitive
performance were observed. Attention/vigilance was the only domain
with SMS participants demonstrating superior cognitive performance
compared to those with schizophrenia (Table 2).
Subsequent analyses were then conducted to examine overall per-
formance differences on the domain measures of neurocognition and
social cognition between SMS patients with high (score, 6–9) ormoder-
ate (score, 4–5) alcohol or cannabis severity. The proportion of patients
comprising these severity groups is presented in Table 1. Results re-
vealed moderate alcohol severity patients (M = 33.88; SE = 5.35)
had better reasoning neurocognitive function than those (M= 13.94;
SE= 2.24)with high alcohol severity (p b .001). However, high alcohol
severity patients (M = 35.48; SE = 1.08) exhibited better emotionperception than those with (M= 30.68; SE= 0.91) moderate alcohol
severity (p b .001). High alcohol severity (M= 101.43; SE= 2.42) pa-
tients also had better emotion management than those with moderate
alcohol (M = 84.85; SE = 1.91) severity (p b .001). No between-
group differences were observed among high or moderate cannabis se-
verity patients (all p N .231) patients. Patient’s not using cannabis with-
in 30 days of enrollment had better emotion processing, attention/
vigilance, and processing speed compared to non-cannabis users within
30 days (all p b .039). No differences were observed between alcohol
users or non-users within 30 days of enrollment (all p N .173).
Prior studies examining the impact of substancemisuse on cognition
in schizophrenia have varied (Potvin et al., 2012). Since such studies
have not adequately addressed the severity associated with misusing
substances, a more extensive examination of these effects is warranted.
We found few differences between SMS and schizophrenia patients, in-
dicating similar degrees of cognitive impairment. Further, recent canna-
bis, but not alcohol use had a negative impact on various cognitive
domains. Interestingly, moderate alcohol severity patients had worse
emotion processing than high alcohol severity patients.
Limitations and implications of this research should be noted. Our
modest sample limits generalizability, with additional limitations in-
cluding a lack of statistical control for chronicity of substance misuse
and schizophrenia, the absence of biomedical testing, and the lack of
sample representativeness. Despite such limitations, our results have
implications for future research. Prior research reports cognitive advan-
tages for SMS (alcohol/cannabis) over schizophrenia patients in terms
of processing speed (Herman, 2004; McCleery et al., 2006; Potvin
et al., 2005; Thoma et al., 2007), but we observed that schizophrenia pa-
tients had better processing speed than SMS patients. Of the studies
reporting improved processing speed in SMS patients, McCleery et al.
(2006) studied ﬁrst-episode patients, Herman (2004) studied inpa-
tients, and both Potvin et al. (2005) and Thoma et al. (2007) included
polysubstancemisusers in their samples.We used an outpatient sample
and did not focus on ﬁrst-episode patients or substances other than al-
cohol/cannabis,whichmay account for differences in ourﬁndings. Aside
from ﬁnding better attention/vigilance in SMS patients, no other
between-group differences were observed, which is consistent with
comparative studies (Barnes et al., 2006; Harrison et al., 2008; Pencer
Table 2
Neurocognitive and social–cognitive test performance of healthy individuals, and participants with schizophrenia-spectrum disorders with and without substance misuse
problems (N = 97).
HC SMS SZ
AnalysisN = 37 N = 32 N = 28
Variable M SE M SE M SE F df p Directiona
Neurocognition Domain
MCCBb
Processing Speed 78.78 4.01 24.17 4.82 41.11 5.85 37.88 2 b .001 HC N SZ N SMS
Attention/Vigilance 53.46 4.99 31.13 5.23 16.00 3.47 20.80 2 b .001 HC N SMS N SZ
Working Memory 53.68 5.03 31.83 5.89 30.11 4.93 6.81 2 b .001 HC N SMS, SZ
Verbal Learning 53.25 4.89 19.76 4.54 32.87 6.20 11.85 2 b .001 HC N SMS, SZ
Reasoning/Problem Solving 56.22 4.78 38.00 4.99 40.55 6.35 3.76 2 .027 HC N SMS
Visual Learning 60.62 4.38 34.48 5.35 25.44 5.73 14.36 2 b .001 HC N SMS, SZ
Social Cognition Domain
MSCEITc
Total Score 100.78 2.30 92.12 2.38 91.02 2.50 5.18 2 .007 HC N SMS, SZ
Emotion Perception 102.62 2.89 98.64 4.17 94.79 3.07 1.89 2 .156 –
Emotion Facilitation 102.37 2.27 97.33 3.49 97.05 2.78 1.15 2 .319 –
Emotion Understanding 102.42 1.85 89.24 2.02 89.00 2.29 15.35 2 b .001 HC N SMS, SZ
Emotion Management 95.19 1.96 90.61 2.28 91.78 1.86 1.32 2 .271 –
Penn Emotion Recognition Test
Accuracy 34.52 0.53 32.27 0.87 32.06 0.78 4.56 2 .013 HC N SZ
Reaction Time (log) 7.57 0.34 7.71 0.06 7.66 0.04 2.22 2 .115 –
Note. HC = Healthy controls; SMS = substancemisusing schizophrenia patients (alcohol or cannabis); SZ = patientswith schizophrenia. Performance differences between study groups
were investigated by using linear mixed-effects models, which were carried out utilizing R version 2.15.0. (R Development Core Team, 2014). Themeans account for age, sex, race, and IQ
differences. Neurocognitive and social–cognitive domain scores were standardized by scaling test items to a common (z) metric. Higher scores indicate better neurocognitive or social
cognitive functioning.
a The statistical signiﬁcance of all pairwise comparisons are adjusted using Hochberg’s (1988) correction.
b MCCB = MATRICS Consensus Cognitive Battery.
c MSCEIT = Mayer–Salovey–Caruso Emotional Intelligence Test.
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strong novelty seeking traits (Dervaux et al., 2001), it has been sug-
gested that such patients have emotion processing deﬁcits (Potvin
et al., 2012). Within our SMS sample, moderate alcohol severity was as-
sociatedwithworse emotion processing, perhaps because such patients
engaged in more novelty seeking behaviors than high alcohol severity
patients. Compared to moderate alcohol severity patients, high alcohol
severity patients may be better positioned to engage in emotional deci-
sion making because such persons no longer experience the intoxicat-
ing effects of the substance. While this explanation may account for
our ﬁnding of better emotion processing in high alcohol severity pa-
tients, the exploratory and unexpected nature in which these results
emerged signals a need for future studies to test these effects in larger
SMS samples. Although our ﬁndings revealed few differences between
SMS and schizophrenia patients overall, the deﬁcits observed in SMSpa-
tients can create difﬁcultieswhen forming social relationships, negotiat-
ing out of dangerous situations, and implementing strategies to abstain
from substancemisuse (Gearon & Bellack, 1999). All of these factors can
interact with cognition; therefore interventions are needed that target
the challenges that areworsened by substancemisuse and the cognitive
deﬁcits affecting these major areas of role functioning. Such patients
may beneﬁt from the novel therapeutics of cognitive remediation
(Eack et al., 2009), which could not only improve their cognitive func-
tion but also help address the problems that are linked with substance
misuse in this population.
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